Lowering the dosage of the chemo drug will make PTX-200 more effective to inhibit AKT to overcome resistance. As for side effects i think they are unrelated to PTX-200, as mentioned not seen in other trials also these are very sick patients who most likely had these conditions prior or developed them whilst very ill.
"Prescient will add an additional exploratory arm of the study to explore PTX-200 in combination with a lower dose of cytarabine in order to best optimize the dose of PTX-200 and best inhibit Akt. A similar modification was made to the PTX-200 study in ovarian cancer, which reduced the amount of chemotherapy (in that case, carboplatin)"
